title: Prognostic value of platelet to lymphocyte ratio in non-small cell lung cancer: evidence from 3,430 patients.
abstract: This study was designed to explore the association between elevated platelet to lymphocyte ratio (PLR) and prognosis of patients with non-small cell lung cancer (NSCLC) by meta-analysis. A total of 11 studies with 3,430 subjects were included and the combined hazard ratio (HR) and 95% confidence intervals (95% CI) were calculated. The data showed that elevated PLR predicted poor overall survival (OS) (HR = 1.42; 95% CI: 1.25-1.61, p < 0.001; I(2) = 63.6, Ph = 0.002) and poor disease-free survival (DFS)/progression-free survival (PFS) (HR = 1.19; 95%CI: 1.02-1.4, p = 0.027; I(2) = 46.8, Ph = 0.111). Subgroup analysis showed elevated PLR did not predict poor OS in patients included in large sample studies (HR = 1.44; 95% CI: 0.94-2.21, p = 0.098) whereas patients with Caucasian ethnicity (HR = 1.59; 95%CI: 1.27-1.98, p < 0.001) and PLR cut-off value > 180 (HR = 1.61; 95%CI: 1.3-1.99, p < 0.001) had enhanced prognostic efficiency for OS. Subgroup analysis also demonstrated that high PLR did not predict poor DFS/PFS in Asian patients. In conclusion, our meta-analysis suggested that elevated PLR was associated with poor OS and DFS/PFS in NSCLC. In addition, high PLR especially predicted poor OS in Caucasians but had no association with poor DFS/PFS in Asians.
authors.affiliation: Department of Radiation Oncology, Peking University First Hospital, Beijing 100034, China.
authors.forename: Xiaobin
authors.initials: X
authors.lastname: Gu
authors.affiliation: Department of Radiation Oncology, Peking University First Hospital, Beijing 100034, China.
authors.forename: Shaoqian
authors.initials: S
authors.lastname: Sun
authors.affiliation: Department of Radiation Oncology, Peking University First Hospital, Beijing 100034, China.
authors.forename: Xian-Shu
authors.initials: XS
authors.lastname: Gao
authors.affiliation: Tangshan People's Hospital, Hebei 063000, China.
authors.forename: Wei
authors.initials: W
authors.lastname: Xiong
authors.affiliation: Department of Radiation Oncology, Peking University First Hospital, Beijing 100034, China.
authors.forename: Shangbin
authors.initials: S
authors.lastname: Qin
authors.affiliation: Department of Radiation Oncology, Peking University First Hospital, Beijing 100034, China.
authors.forename: Xin
authors.initials: X
authors.lastname: Qi
authors.affiliation: Department of Radiation Oncology, Peking University First Hospital, Beijing 100034, China.
authors.forename: Mingwei
authors.initials: M
authors.lastname: Ma
authors.affiliation: Department of Radiation Oncology, Peking University First Hospital, Beijing 100034, China.
authors.forename: Xiaoying
authors.initials: X
authors.lastname: Li
authors.affiliation: Department of Radiation Oncology, Peking University First Hospital, Beijing 100034, China.
authors.forename: Dong
authors.initials: D
authors.lastname: Zhou
authors.affiliation: Department of Radiation Oncology, Peking University First Hospital, Beijing 100034, China.
authors.forename: Wen
authors.initials: W
authors.lastname: Wang
authors.affiliation: Department of Radiation Oncology, Peking University First Hospital, Beijing 100034, China.
authors.forename: Hao
authors.initials: H
authors.lastname: Yu
mesh_terms: D002289:Carcinoma, Non-Small-Cell Lung / Q000097:blood / Q000175:diagnosis* / Q000276:immunology / Q000401:mortality; D018572:Disease-Free Survival; D006801:Humans; D008175:Lung Neoplasms / Q000097:blood / Q000175:diagnosis* / Q000276:immunology / Q000401:mortality; D018655:Lymphocyte Count; D010976:Platelet Count; D011379:Prognosis; D016016:Proportional Hazards Models